MPM BioImpact’s Entrada Therapeutics TRDA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,253,053
Closed -$9.22M – 46
2026
Q2
$9.22M Buy
+1,253,053
New +$12M 0.56% 34

Other funds holding TRDA

MPM BioImpact's TRDA Position: Q3 2026 in Review

MPM BioImpact sold out of Entrada Therapeutics (TRDA) in Q3 2026, closing a stake of 1,253,053 shares — an estimated $9.22M sold.

MPM BioImpact first reported a position in TRDA in Q2 2026 and held it in 1 quarter. The position peaked at $9.22M in Q2 2026. 132 funds tracked by Wall St. Rank hold TRDA as of Q3 2026.

  • MPM BioImpact reported no remaining Entrada Therapeutics position as of Q3 2026 after selling out during the quarter.
  • MPM BioImpact sold 1,253,053 Entrada Therapeutics shares in Q3 2026, an estimated $9.22M.
  • MPM BioImpact first reported a position in Entrada Therapeutics in Q2 2026 and held it in 1 quarter.
  • MPM BioImpact's Entrada Therapeutics position peaked at $9.22M in Q2 2026.
  • 132 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q3 2026.

Based on MPM BioImpact's 13F filing for Q3 2026, filed 16 Nov 2026.